Jun Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jun Chen has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Richard L. Ehman
Department of Radiology Mayo Clinic Rochester Minnesota USA
5 shared publications Kevin J. Glaser
Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
3 shared publications- Meng Yin
Department of Radiology Mayo Clinic Rochester Minnesota USA
3 shared publications Richard L. Ehman
Department of Radiology, Mayo Clinic, Rochester, MN, USA
3 shared publications- Bing Zhang
Department of Radiology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China
2 shared publications - Javier A. Tamargo
University of Florida
2 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Liver CT-based composite biomarkers can identify MASH and steatosis grade in people with obesity prior to bariatric surgery: a retrospective study
Background: Hepatic steatosis is a precursor to metabolic dysfunction-associated steatohepatitis (MASH), which is linked to obesity and diabetes and poses a risk for liver cirrhosis and cancer. For detecting MASH and hepatic steatosis, liver biopsy is the reference method, but it is invasive and impractical for repeated monitoring of treatment efficacy. Our goal was to develop a convenient and non-invasive tool for accurately identifying MASH and steatosis grade in people with obesity. Methods: This retrospective study included 321 people with obesity who underwent bariatric surgery, during which liver biopsies were also performed. Clinical characteristics, presurgical computed tomography (CT)-derived parameters, magnetic resonance imaging proton density fat fraction (MRI-PDFF), and CT-based skeletal muscle index (SMI) were obtained. Results: A convenient model consisting of liver CT attenuation value (CT Liver ), alanine aminotransferase (ALT) and high-density lipoprotein cholesterol (HDL-C) was developed for identifying MASH, with area under the curve (AUC) of 0.799. To predict hepatic steatosis of grade ≥ 1, ≥ 2 and 3, the AUCs of CT Liver -based combination models were 0.954, 0.927, and 0.894, respectively. The diagnostic performance of the CT Liver -based combination models was comparable to that of liver MRI-PDFF in identifying different hepatic steatosis grades (Delong’s test, p > 0.05). CT-based SMI was significantly positively correlated with hepatic steatosis grade ( r = 0.12, p = 0.031) and non-alcoholic fatty liver disease (NAFLD) activity score ( r = 0.18, p = 0.002). Conclusions: The liver CT-based composite biomarkers can identify MASH and hepatic steatosis grade with high diagnostic performance in people with obesity, providing a non-invasive, accessible, and practical supplementary tool for clinical stratified management.
- 14 May 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Open AccessLiver CT-based composite biomarkers can identify MASH and steatosis grade in people with obesity prior to bariatric surgery: a retrospective study
Background: Hepatic steatosis is a precursor to metabolic dysfunction-associated steatohepatitis (MASH), which is linked to obesity and diabetes and poses a risk for liver cirrhosis and cancer. For detecting MASH and hepatic steatosis, liver biopsy is the reference method, but it is invasive and impractical for repeated monitoring of treatment efficacy. Our goal was to develop a convenient and non-invasive tool for accurately identifying MASH and steatosis grade in people with obesity. Methods: This retrospective study included 321 people with obesity who underwent bariatric surgery, during which liver biopsies were also performed. Clinical characteristics, presurgical computed tomography (CT)-derived parameters, magnetic resonance imaging proton density fat fraction (MRI-PDFF), and CT-based skeletal muscle index (SMI) were obtained. Results: A convenient model consisting of liver CT attenuation value (CT Liver ), alanine aminotransferase (ALT) and high-density lipoprotein cholesterol (HDL-C) was developed for identifying MASH, with area under the curve (AUC) of 0.799. To predict hepatic steatosis of grade ≥ 1, ≥ 2 and 3, the AUCs of CT Liver -based combination models were 0.954, 0.927, and 0.894, respectively. The diagnostic performance of the CT Liver -based combination models was comparable to that of liver MRI-PDFF in identifying different hepatic steatosis grades (Delong’s test, p > 0.05). CT-based SMI was significantly positively correlated with hepatic steatosis grade ( r = 0.12, p = 0.031) and non-alcoholic fatty liver disease (NAFLD) activity score ( r = 0.18, p = 0.002). Conclusions: The liver CT-based composite biomarkers can identify MASH and hepatic steatosis grade with high diagnostic performance in people with obesity, providing a non-invasive, accessible, and practical supplementary tool for clinical stratified management.
- Top Cited PapersOpen Access
- 11 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 1562
Multi-modal AI for opportunistic screening, staging and progression risk stratification of steatotic liver disease
The global rise in steatotic liver disease poses a significant public health challenge. While non-contrast computed tomography scans hold promise for opportunistic detection of steatotic liver disease, their potential for staging and risk assessment remains underexplored. Here we present a multimodal AI model trained on a large dataset, comprising of (n=968) histopathologically and (n=1103) radiologically confirmed cases, validated against both histology (n=660) and MRI-PDFF (n=375) gold standards, demonstrating high accuracy in detecting mild to severe steatosis (AUC: 0.904-0.929) and clinically significant fibrosis (AUC: 0.824-0.888). Furthermore, integrating the model into the standard clinical pathway improves primary risk screening in a retrospective patient cohort (n=1192), identifying 36% more patients at risk of fibrosis progression. Using Cox proportional hazard model, we observe that the intermediate-high risk patients identified by the optimized clinical pathway exhibits a significantly higher incidence of cirrhosis (hazard ratio: 5.54: 2.69-11.42), showcasing the model's potential for early detection and management of steatotic liver disease.
- 11 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 1562
Top Cited PapersOpen AccessMulti-modal AI for opportunistic screening, staging and progression risk stratification of steatotic liver disease
The global rise in steatotic liver disease poses a significant public health challenge. While non-contrast computed tomography scans hold promise for opportunistic detection of steatotic liver disease, their potential for staging and risk assessment remains underexplored. Here we present a multimodal AI model trained on a large dataset, comprising of (n=968) histopathologically and (n=1103) radiologically confirmed cases, validated against both histology (n=660) and MRI-PDFF (n=375) gold standards, demonstrating high accuracy in detecting mild to severe steatosis (AUC: 0.904-0.929) and clinically significant fibrosis (AUC: 0.824-0.888). Furthermore, integrating the model into the standard clinical pathway improves primary risk screening in a retrospective patient cohort (n=1192), identifying 36% more patients at risk of fibrosis progression. Using Cox proportional hazard model, we observe that the intermediate-high risk patients identified by the optimized clinical pathway exhibits a significantly higher incidence of cirrhosis (hazard ratio: 5.54: 2.69-11.42), showcasing the model's potential for early detection and management of steatotic liver disease.
- 21 June 2024
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 112, 54-62
3D vector MR elastography applications in small organs
- 21 June 2024
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 112, 54-62
3D vector MR elastography applications in small organs
- 12 March 2024
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 109, 173-179
3D MR elastography-based stiffness as a marker for predicting tumor grade and subtype in cervical cancer
- 12 March 2024
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 109, 173-179
3D MR elastography-based stiffness as a marker for predicting tumor grade and subtype in cervical cancer
- Open Access
- 30 August 2022
- Published by AccScience Publishing in Advanced Neurology
- Vol. 1 (2) , 145
Neuroimaging associations with spatial navigation impairment in Alzheimer’s disease continuum: A narrative review
Identifying individuals with incipient Alzheimer’s disease (AD) are critical for early and targeted intervention before the dementia develops as AD progresses. Recently, emerging data have suggested that spatial navigation and neuroimaging could be utilized to identify individuals with prodromal AD. Compared to episodic memory, spatial navigation has fewer cultural and educational discrepancies and could serve as a promising marker for diagnosis and outcome measures in multicenter longitudinal studies with large cohorts. Furthermore, neuroimaging studies have contributed to our understanding of the structural and functional neural basis underlying spatial navigation and provided sensitive and non-invasive neuroimaging markers. The current review summarizes neuroimaging associations with spatial navigation impairment in the AD continuum, their potential pathophysiological mechanisms, and nonpharmacological interventions for spatial navigation impairments. We highlight the promising role of spatial navigation in the early identification of the preclinical and prodromal patients with potential risk of developing AD dementia. Multicenter large-scale longitudinal studies on patients across the AD continuum coupled with a standardized routine assessment of spatial navigation abilities in clinical settings are needed. This review may have implications for clinical practice and future research directions.
- 30 August 2022
- Published by AccScience Publishing in Advanced Neurology
- Vol. 1 (2) , 145
Open AccessNeuroimaging associations with spatial navigation impairment in Alzheimer’s disease continuum: A narrative review
Identifying individuals with incipient Alzheimer’s disease (AD) are critical for early and targeted intervention before the dementia develops as AD progresses. Recently, emerging data have suggested that spatial navigation and neuroimaging could be utilized to identify individuals with prodromal AD. Compared to episodic memory, spatial navigation has fewer cultural and educational discrepancies and could serve as a promising marker for diagnosis and outcome measures in multicenter longitudinal studies with large cohorts. Furthermore, neuroimaging studies have contributed to our understanding of the structural and functional neural basis underlying spatial navigation and provided sensitive and non-invasive neuroimaging markers. The current review summarizes neuroimaging associations with spatial navigation impairment in the AD continuum, their potential pathophysiological mechanisms, and nonpharmacological interventions for spatial navigation impairments. We highlight the promising role of spatial navigation in the early identification of the preclinical and prodromal patients with potential risk of developing AD dementia. Multicenter large-scale longitudinal studies on patients across the AD continuum coupled with a standardized routine assessment of spatial navigation abilities in clinical settings are needed. This review may have implications for clinical practice and future research directions.
- Open Access
PNPLA3 Single Nucleotide Polymorphism Prevalence and Association with Liver Disease in a Diverse Cohort of Persons Living with HIV
In persons living with HIV (PLWH), there are multiple sources of liver injury. Gene polymorphisms of PNPLA3 (patatin-like phospholipase domain-containing protein 3) have been identified as an important cofactor for increased disease severity in both alcoholic and non-alcoholic steatohepatitis (NASH). We utilized a well-characterized cohort of ethnically and racially diverse patients with HIV to define the prevalence of PNPLA3 SNPs (single nucleotide polymorphism) (rs738409), and to determine the relationship to hepatic steatosis and liver fibrosis. Steatosis was determined using MRI-PDFF (magnetic resonance imaging-determined proton density fat fraction) and fibrosis was estimated using MR Elastography (MRE). From the Miami Area HIV Study (MASH) cohort, 100 HIV positive participants and 40 controls (HCV/HIV = 20; HCV and HIV negative = 20) were evaluated. Nearly 40% of all participants carried the variant G allele associated with increased liver disease severity and 5% were homozygotic GG. The variant SNP occurred most frequently in those self-identified as Hispanic compared to white or Black participants. Hepatic steatosis (>5% fat) was present significantly more often in those without HIV vs. those with (p < 0.001). Putative NAFLD/NASH was found to be present in 6% of tested subjects, who were HIV monoinfected. BMI was lower in those that carried the G allele for PNPLA3. This finding suggests that PNPLA3 may be an independent component to NAFLD (non-alcoholic fatty liver disease)/NASH development and longitudinal follow-up of the cohort is warranted.
Open AccessPNPLA3 Single Nucleotide Polymorphism Prevalence and Association with Liver Disease in a Diverse Cohort of Persons Living with HIV
In persons living with HIV (PLWH), there are multiple sources of liver injury. Gene polymorphisms of PNPLA3 (patatin-like phospholipase domain-containing protein 3) have been identified as an important cofactor for increased disease severity in both alcoholic and non-alcoholic steatohepatitis (NASH). We utilized a well-characterized cohort of ethnically and racially diverse patients with HIV to define the prevalence of PNPLA3 SNPs (single nucleotide polymorphism) (rs738409), and to determine the relationship to hepatic steatosis and liver fibrosis. Steatosis was determined using MRI-PDFF (magnetic resonance imaging-determined proton density fat fraction) and fibrosis was estimated using MR Elastography (MRE). From the Miami Area HIV Study (MASH) cohort, 100 HIV positive participants and 40 controls (HCV/HIV = 20; HCV and HIV negative = 20) were evaluated. Nearly 40% of all participants carried the variant G allele associated with increased liver disease severity and 5% were homozygotic GG. The variant SNP occurred most frequently in those self-identified as Hispanic compared to white or Black participants. Hepatic steatosis (>5% fat) was present significantly more often in those without HIV vs. those with (p < 0.001). Putative NAFLD/NASH was found to be present in 6% of tested subjects, who were HIV monoinfected. BMI was lower in those that carried the G allele for PNPLA3. This finding suggests that PNPLA3 may be an independent component to NAFLD (non-alcoholic fatty liver disease)/NASH development and longitudinal follow-up of the cohort is warranted.
- 1 March 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 220, 108531
Heroin use is associated with liver fibrosis in the Miami Adult Studies on HIV (MASH) cohort
- 1 March 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 220, 108531
Heroin use is associated with liver fibrosis in the Miami Adult Studies on HIV (MASH) cohort
- 1 December 2017
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 44, 92-95
Static and dynamic liver stiffness: An ex vivo porcine liver study using MR elastography
- 1 December 2017
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 44, 92-95
Static and dynamic liver stiffness: An ex vivo porcine liver study using MR elastography
- 26 September 2017
- Published by Springer Nature in Abdominal Radiology
- Vol. 43 (6) , 1456-1463
Uterine fibroids: correlations between MRI appearance and stiffness via magnetic resonance elastography
Rationale and objectives Magnetic resonance elastography has proven to be a valuable tool in the diagnosis of liver fibrosis, breast and cervical cancer, but its application in uterine fibroids requires further characterization. The aim of the present study was to examine the relationship between uterine fibroid stiffness by MRE and MR imaging characteristics. Materials and methods An IRB-approved, HIPAA compliant review was performed of prospectively collected pelvic MRI and 2D-MRE data in patients with symptomatic uterine fibroids (N = 102). T1 and T2 weighted pelvic MRI with gadolinium enhancement were performed. In a small patient subset, fibroid stiffness was assessed by both 2D and 3D MRE. Fibroid stiffness by modality or imaging characteristics was analyzed using one-way analysis of variance followed by Student t test. Results Four fibroid groups were identified based on T2 appearance: Isointense (N = 7), bright (N = 6), dark with minimal heterogeneity (N = 69), and dark with substantial heterogeneity (N = 20). Mean fibroid stiffness was 4.81 ± 2.12 kPa. Comparison of fibroid stiffness by T2 signal intensity showed that T2 bright fibroids were significantly less stiff than fibroids appearing T2 dark with minimal heterogeneity (mean stiffness difference = 2.38 kPa; p < 0.05) and T2 dark fibroids with substantial heterogeneity were significantly less stiff than T2 dark fibroids with minimal heterogeneity (mean difference = 1.25 kPa; p < 0.05). There was no significant association between fibroid stiffness and T1 signal characteristics or gadolinium enhancement. There was no significant difference in stiffness values obtained by either 2D vs. 3D MRE. Conclusions These data suggest differences in fibroid stiffness are associated with different T2 imaging characteristics with less stiff fibroids being T2 bright and more stiff fibroids being T2 dark. Further studies are needed to determine if fibroid stiffness by MRE may serve as an imaging biomarker to help predict MR-guided treatment response.
- 26 September 2017
- Published by Springer Nature in Abdominal Radiology
- Vol. 43 (6) , 1456-1463
Uterine fibroids: correlations between MRI appearance and stiffness via magnetic resonance elastography
Rationale and objectives Magnetic resonance elastography has proven to be a valuable tool in the diagnosis of liver fibrosis, breast and cervical cancer, but its application in uterine fibroids requires further characterization. The aim of the present study was to examine the relationship between uterine fibroid stiffness by MRE and MR imaging characteristics. Materials and methods An IRB-approved, HIPAA compliant review was performed of prospectively collected pelvic MRI and 2D-MRE data in patients with symptomatic uterine fibroids (N = 102). T1 and T2 weighted pelvic MRI with gadolinium enhancement were performed. In a small patient subset, fibroid stiffness was assessed by both 2D and 3D MRE. Fibroid stiffness by modality or imaging characteristics was analyzed using one-way analysis of variance followed by Student t test. Results Four fibroid groups were identified based on T2 appearance: Isointense (N = 7), bright (N = 6), dark with minimal heterogeneity (N = 69), and dark with substantial heterogeneity (N = 20). Mean fibroid stiffness was 4.81 ± 2.12 kPa. Comparison of fibroid stiffness by T2 signal intensity showed that T2 bright fibroids were significantly less stiff than fibroids appearing T2 dark with minimal heterogeneity (mean stiffness difference = 2.38 kPa; p < 0.05) and T2 dark fibroids with substantial heterogeneity were significantly less stiff than T2 dark fibroids with minimal heterogeneity (mean difference = 1.25 kPa; p < 0.05). There was no significant association between fibroid stiffness and T1 signal characteristics or gadolinium enhancement. There was no significant difference in stiffness values obtained by either 2D vs. 3D MRE. Conclusions These data suggest differences in fibroid stiffness are associated with different T2 imaging characteristics with less stiff fibroids being T2 bright and more stiff fibroids being T2 dark. Further studies are needed to determine if fibroid stiffness by MRE may serve as an imaging biomarker to help predict MR-guided treatment response.
- 1 February 2016
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 34 (2) , 91-96
Quantification of regional aortic stiffness using MR elastography: A phantom and ex-vivo porcine aorta study
- 1 February 2016
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 34 (2) , 91-96
Quantification of regional aortic stiffness using MR elastography: A phantom and ex-vivo porcine aorta study